Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
UST demonstrated superior 52-week treatment persistence in IBD patients previously treated with VDZ compared to anti-TNF agents, albeit with a need for more frequent dose adjustments.
Authors
- Cheng‐Tang Chiu (ORCID: https://orcid.org/0000-0002-7437-8052)
- Puo‐Hsien Le (ORCID: https://orcid.org/0000-0002-1100-5371)
- Ming‐Wei Lai (ORCID: https://orcid.org/0000-0002-3570-8565)
- Ren‐Chin Wu (ORCID: https://orcid.org/0000-0003-1439-0874)
- Chyi‐Liang Chen (ORCID: https://orcid.org/0000-0003-4591-0924)
- Yu‐Bin Pan (ORCID: https://orcid.org/0000-0002-2004-1526)
- Chia‐Jung Kuo (ORCID: https://orcid.org/0000-0003-2845-6248)
- Chien‐Ming Chen (ORCID: https://orcid.org/0000-0001-7829-1504)
- Horng-Yih Chiu
Institutions
- Chien Hsin University of Science and Technology (TW)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Taoyuan Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- Taiwan Nurses Association (TW)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1186/s12876-024-03577-1
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- Chang Gung Medical Foundation
- Chang Gung Memorial Hospital, Linkou